2018
Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies
Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, Paige E, Paul DS, Sweeting M, Burgess S, Bell S, Astle W, Stevens D, Koulman A, Selmer RM, Verschuren WMM, Sato S, Njølstad I, Woodward M, Salomaa V, Nordestgaard BG, Yeap BB, Fletcher A, Melander O, Kuller LH, Balkau B, Marmot M, Koenig W, Casiglia E, Cooper C, Arndt V, Franco OH, Wennberg P, Gallacher J, de la Cámara AG, Völzke H, Dahm CC, Dale CE, Bergmann MM, Crespo CJ, van der Schouw YT, Kaaks R, Simons LA, Lagiou P, Schoufour JD, Boer JMA, Key TJ, Rodriguez B, Moreno-Iribas C, Davidson KW, Taylor JO, Sacerdote C, Wallace RB, Quiros JR, Tumino R, Blazer DG, Linneberg A, Daimon M, Panico S, Howard B, Skeie G, Strandberg T, Weiderpass E, Nietert PJ, Psaty BM, Kromhout D, Salamanca-Fernandez E, Kiechl S, Krumholz HM, Grioni S, Palli D, Huerta JM, Price J, Sundström J, Arriola L, Arima H, Travis RC, Panagiotakos DB, Karakatsani A, Trichopoulou A, Kühn T, Grobbee DE, Barrett-Connor E, van Schoor N, Boeing H, Overvad K, Kauhanen J, Wareham N, Langenberg C, Forouhi N, Wennberg M, Després JP, Cushman M, Cooper JA, Rodriguez CJ, Sakurai M, Shaw JE, Knuiman M, Voortman T, Meisinger C, Tjønneland A, Brenner H, Palmieri L, Dallongeville J, Brunner EJ, Assmann G, Trevisan M, Gillum RF, Ford I, Sattar N, Lazo M, Thompson SG, Ferrari P, Leon DA, Smith GD, Peto R, Jackson R, Banks E, Di Angelantonio E, Danesh J, Group E, Wood A, Kaptoge S, Butterworth A, Willeit P, Warnakula S, Bolton T, Paige E, Paul D, Sweeting M, Burgess S, Bell S, Astle W, Stevens D, Koulman A, Selmer R, Verschuren M, Sato S, Njølstad I, Woodward M, Veikko S, Nordestgaard B, Yeap B, Flecther A, Melander O, Kuller L, Balkau B, Marmot M, Koenig W, Casiglia E, Cooper C, Arndt V, Franco O, Wennberg P, Gallacher J, de la Cámara A, Völzke H, Dahm C, Dale C, Bergmann M, Crespo C, van der Schouw Y, Kaaks R, Simons L, Lagiou P, Schoufour J, Boer J, Key T, Rodriguez B, Moreno-Iribas C, Davidson K, Taylor J, Sacerdote C, Wallace R, Quiros J, Rimm E, Tumino R, Blazer D, Linneberg A, Daimon M, Panico S, Howard B, Skeie G, Salomaa V, Strandberg T, Weiderpass E, Nietert P, Psaty B, Kromhout D, Salamanca-Fernandez E, Kiechl S, Krumholz H, Grioni S, Palli D, Huerta J, Price J, Sundström J, Arriola L, Arima H, Travis R, Panagiotakos D, Karakatsani A, Trichopoulou A, Kühn T, Grobbee D, Barrett-Connor E, van Schoor N, Boeing H, Overvad K, Kauhanen J, Wareham N, Langenberg C, Forouhi N, Wennberg M, Després J, Cushman M, Cooper J, Rodriguez C, Sakurai M, Shaw J, Knuiman M, Voortman T, Meisinger C, Tjønneland A, Brenner H, Palmieri L, Dallongeville J, Brunner E, Assmann G, Trevisan M, Gillumn R, Ford I, Sattar N, Lazo M, Thompson S, Ferrari P, Leon D, Smith G, Peto R, Jackson R, Banks E, Di Angelantonio E, Danesh J. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. The Lancet 2018, 391: 1513-1523. PMID: 29676281, PMCID: PMC5899998, DOI: 10.1016/s0140-6736(18)30134-x.Peer-Reviewed Original ResearchConceptsIndividual participant dataCardiovascular disease subtypesCause mortalityCurrent drinkersCardiovascular diseaseHazard ratioAlcohol consumptionMyocardial infarctionLower riskProspective studyHigh-income countriesDisease subtypesIncident cardiovascular disease eventsFatal aortic aneurysmsMinimum mortality riskTotal cardiovascular diseasePrevious cardiovascular diseaseCardiovascular disease eventsHistory of diabetesDose-response associationUK Medical Research CouncilAge 40 yearsAlcohol consumption amountBritish Heart FoundationWeeks of alcohol
2017
Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines A Cost-Effectiveness Analysis
Hong JC, Blankstein R, Shaw LJ, Padula WV, Arrieta A, Fialkow JA, Blumenthal RS, Blaha MJ, Krumholz HM, Nasir K. Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines A Cost-Effectiveness Analysis. JACC Cardiovascular Imaging 2017, 10: 938-952. PMID: 28797417, DOI: 10.1016/j.jcmg.2017.04.014.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAmerican Heart AssociationBayes TheoremClinical Decision-MakingComputer SimulationCoronary AngiographyCoronary Artery DiseaseCoronary VesselsCost-Benefit AnalysisDecision Support TechniquesDrug CostsFemaleGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedModels, EconomicMonte Carlo MethodMultivariate AnalysisPractice Guidelines as TopicPredictive Value of TestsQuality of LifeQuality-Adjusted Life YearsTime FactorsTreatment OutcomeUnited StatesVascular CalcificationConceptsCoronary artery calciumQuality-adjusted life yearsStatin therapyArtery calciumLong-term statin therapyAtherosclerotic cardiovascular disease eventsCholesterol management guidelinesIncremental cost-effectiveness ratioCardiovascular disease eventsAtherosclerotic cardiovascular diseaseCost-effectiveness ratioCost-effectiveness analysisStatin candidatesCholesterol managementCardiovascular diseaseTreatment decisionsAmerican CollegeDisease eventsLifetime horizonLife yearsAmerican HeartSocietal perspectiveManagement guidelinesStatinsPatients
2015
Achieving best outcomes for patients with cardiovascular disease in China by enhancing the quality of medical care and establishing a learning health-care system
Jiang L, Krumholz HM, Li X, Li J, Hu S. Achieving best outcomes for patients with cardiovascular disease in China by enhancing the quality of medical care and establishing a learning health-care system. The Lancet 2015, 386: 1493-1505. PMID: 26466053, PMCID: PMC5323019, DOI: 10.1016/s0140-6736(15)00343-8.Peer-Reviewed Original Research
2003
Are Statins Indicated for the Primary Prevention of CAD in Octogenarians? Angagonist Viewpoint
Foody JM, Krumholz HM. Are Statins Indicated for the Primary Prevention of CAD in Octogenarians? Angagonist Viewpoint. The American Journal Of Geriatric Cardiology 2003, 12: 357-360. PMID: 14610384, DOI: 10.1111/j.1076-7460.2003.02912.x.Peer-Reviewed Original ResearchConceptsCoronary artery diseasePrimary preventionArtery diseaseOvert coronary artery diseaseRisk of myositisCardiovascular disease eventsRole of statinsUse of statinsAge 65 yearsBalance of risksCardiovascular eventsStatin therapyPatient preferencesCholesterol levelsCardiovascular diseaseOctogenariansClinical uncertaintyDisease eventsCurrent evidenceStatinsAge groupsDiseasePreventionRiskMyositis